We urge you to utilize analysis of Digirad fundamentals to see if markets are presently mispricing the company. We found thirty-seven available fundamental indicators for Digirad Corporation which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Digirad fundamentals including its Shares Outstanding, Price to Sales, Cash per Share, as well as the relationship between Number of Shares Shorted and EBITDA . Please also check Digirad Corporation Price to Earning to verify the company can sustain itself down the road.Use Digirad to enhance returns of your portfolios. The stock experiences large bullish trend. Check odds of Digirad to be traded at $2.57 in 30 days
Digirad Valuation Over Time
Digirad Company SummaryDigirad competes with Edwards Lifesciences, DarioHealth Corp. Digirad Corporation operates in two segments Diagnostic Services and Diagnostic Imaging. The Diagnostic Services segment offer inoffice nuclear cardiology and ultrasound services and cardiac event monitoring services to physicians who perform nuclear imaging echocardiography vascular or general ultrasound tests or any combination of these procedures in their offices hospitals and imaging centers. The Diagnostic Imaging segment sells nuclear imaging cameras for nuclear cardiology and general nuclear medicine applications as well as offer camera maintenance services to hospitals imaging centers physician offices and mobile service providers. Digirad Corporationration was founded in 1985 and is headquartered in Suwanee Georgia.
Digirad Current Asset vs Beta
Digirad Corporation is rated # 2 in current asset category among related companies. It is rated # 2 in beta category among related companies . The ratio of Current Asset to Beta for Digirad Corporation is about 14,766,047